Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
ALNOV Stock Overview
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa.
Novacyt Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €1.78 |
52 Week High | €5.89 |
52 Week Low | €1.60 |
Beta | -2.93 |
1 Month Change | -21.13% |
3 Month Change | -15.45% |
1 Year Change | -55.45% |
3 Year Change | 1,437.93% |
5 Year Change | 85.83% |
Change since IPO | -79.49% |
Recent News & Updates
With EPS Growth And More, Novacyt (EPA:ALNOV) Is Interesting
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Shareholder Returns
ALNOV | FR Biotechs | FR Market | |
---|---|---|---|
7D | -5.9% | 3.6% | -1.5% |
1Y | -55.4% | -39.9% | -18.8% |
Return vs Industry: ALNOV underperformed the French Biotechs industry which returned -39% over the past year.
Return vs Market: ALNOV underperformed the French Market which returned -5.4% over the past year.
Price Volatility
ALNOV volatility | |
---|---|
ALNOV Average Weekly Movement | 13.4% |
Biotechs Industry Average Movement | 8.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in FR Market | 10.2% |
10% least volatile stocks in FR Market | 3.5% |
Stable Share Price: ALNOV is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: ALNOV's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 276 | David Allmond | https://www.novacyt.com |
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases.
Novacyt Fundamentals Summary
ALNOV fundamental statistics | |
---|---|
Market Cap | UK£107.07m |
Earnings (TTM) | -UK£9.73m |
Revenue (TTM) | UK£95.78m |
1.1x
P/S Ratio-11.0x
P/E RatioIs ALNOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ALNOV income statement (TTM) | |
---|---|
Revenue | UK£95.78m |
Cost of Revenue | UK£30.91m |
Gross Profit | UK£64.87m |
Other Expenses | UK£74.60m |
Earnings | -UK£9.73m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | -0.14 |
Gross Margin | 67.73% |
Net Profit Margin | -10.16% |
Debt/Equity Ratio | 0% |
How did ALNOV perform over the long term?
See historical performance and comparisonValuation
Is Novacyt undervalued compared to its fair value and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
0.75x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: ALNOV (€1.78) is trading above our estimate of fair value (€0.01)
Significantly Below Fair Value: ALNOV is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ALNOV is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: ALNOV is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALNOV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALNOV is good value based on its PB Ratio (0.8x) compared to the FR Biotechs industry average (2.6x).
Future Growth
How is Novacyt forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
48.8%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if ALNOV's forecast earnings growth is above the savings rate (0.3%).
Earnings vs Market: Insufficient data to determine if ALNOV's earnings are forecast to grow faster than the French market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if ALNOV's revenue is forecast to grow faster than the French market.
High Growth Revenue: Insufficient data to determine if ALNOV's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALNOV's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Novacyt performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
61.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALNOV is currently unprofitable.
Growing Profit Margin: ALNOV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALNOV is unprofitable, but has reduced losses over the past 5 years at a rate of 61.9% per year.
Accelerating Growth: Unable to compare ALNOV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALNOV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: ALNOV has a negative Return on Equity (-6.86%), as it is currently unprofitable.
Financial Health
How is Novacyt's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: ALNOV's short term assets (£158.8M) exceed its short term liabilities (£38.9M).
Long Term Liabilities: ALNOV's short term assets (£158.8M) exceed its long term liabilities (£3.0M).
Debt to Equity History and Analysis
Debt Level: ALNOV is debt free.
Reducing Debt: ALNOV has no debt compared to 5 years ago when its debt to equity ratio was 35.3%.
Debt Coverage: ALNOV has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ALNOV has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Novacyt current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALNOV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALNOV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALNOV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALNOV's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALNOV has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
1.3yrs
Average management tenure
CEO
David Allmond (51 yo)
0.58
Tenure
Mr. David James Allmond serves as Chief Executive Officer and Director of Novacyt S.A. since October 18, 2021. He served as Chief Business Officer of Amryt Pharma Plc until November 2021. He served as Chie...
Leadership Team
Experienced Management: ALNOV's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
Experienced Board: ALNOV's board of directors are considered experienced (4.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ALNOV insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Novacyt S.A.'s employee growth, exchange listings and data sources
Key Information
- Name: Novacyt S.A.
- Ticker: ALNOV
- Exchange: ENXTPA
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €125.976m
- Shares outstanding: 70.61m
- Website: https://www.novacyt.com
Number of Employees
Location
- Novacyt S.A.
- 13 Avenue Morane Saulnier
- Vélizy-Villacoublay
- Ile-de-France
- 78140
- France
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/23 00:00 |
End of Day Share Price | 2022/05/23 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.